Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11193129 Modulatory polynucleotides

Patent 11193129 was granted and assigned to Voyager Therapeutics on December, 2021 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Voyager Therapeutics

Current Assignee

Voyager Therapeutics

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

11193129

Date of Patent

December 7, 2021

Patent Application Number

16749293

Date Filed

January 22, 2020

Patent Citations Received

‌

US Patent 12084659 Modulatory polynucleotides

‌

US Patent 12071625 Modulatory polynucleotides

‌

US Patent 12123002 Compositions and methods of treating amyotrophic lateral sclerosis (ALS)

‌

US Patent 12116589 Treatment of amyotrophic lateral sclerosis (ALS)

‌

US Patent 11752181 Compositions and methods of treating Huntington's disease

‌

US Patent 11931375 Treatment of amyotrophic lateral sclerosis (ALS)

‌

US Patent 11951121 Compositions and methods for treating Huntington's disease

Patent Primary Examiner

‌

Brian Whiteman

Patent abstract

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of modulatory polynucleotides.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11193129 Modulatory polynucleotides

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API